Solving the hardest problems in cell therapy.

Developing effective cell therapies for solid tumors is one of the most challenging endeavors in modern medicine. While these treatments achieve remarkable success in blood cancers, the majority fail when applied to solid tumors.

The challenge isn't the therapy itself—it's access. Most immune cells simply can't reach solid tumor sites, creating a fundamental bottleneck that limits therapeutic success.

We're changing that. Through predictive cell characterization, we identify which immune cells have the best chance of infiltrating tumors—at the most critical decision points from early development through clinical trials.